NO20041994L - Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser - Google Patents

Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser

Info

Publication number: NO20041994L
Authority: NO; Norway
Prior art keywords: preparation; propion; oxy; pharmaceutically; alpha
Prior art date: 2001-10-16

Application number

NO20041994A

Other languages

English (en)

Inventor

Ranjan Chakrabarti

Javed Iqbal

Debnath Bhuniva

Saibal Kumar Das

Gurram Ranga Madhavan

Mohan Chander

Sankar Mohan

Original Assignee

Reddys Lab Ltd Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-16

Filing date

2004-05-14

Publication date

2004-05-14

2004-05-14 Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr

2004-05-14 Publication of NO20041994L publication Critical patent/NO20041994L/no

Links

150000001875 compounds Chemical class 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20041994A 2001-10-16 2004-05-14 Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser NO20041994L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN848CH2001		2001-10-16
PCT/IB2002/004274 WO2003033456A1 (en)	2001-10-16	2002-10-15	NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS

Publications (1)

Publication Number	Publication Date
NO20041994L true NO20041994L (no)	2004-05-14

Family

ID=11097010

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20041994A NO20041994L (no)	2001-10-16	2004-05-14	Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser
NO20041998A NO20041998L (no)	2001-10-16	2004-05-14	Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20041998A NO20041998L (no)	2001-10-16	2004-05-14	Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem

Country Status (14)

Country	Link
US (2)	US20110105748A1 (no)
EP (2)	EP1436247A1 (no)
JP (2)	JP2005527480A (no)
CN (2)	CN1596249A (no)
BR (2)	BR0213380A (no)
CA (2)	CA2463685A1 (no)
HR (2)	HRP20040349A2 (no)
HU (2)	HUP0401649A3 (no)
IL (2)	IL161431A0 (no)
NO (2)	NO20041994L (no)
NZ (1)	NZ532285A (no)
PL (2)	PL369655A1 (no)
WO (2)	WO2003033456A1 (no)
ZA (2)	ZA200402858B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1680397A2 (en) *	2003-10-28	2006-07-19	Dr. Reddy's Laboratories Ltd.	Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
ITRM20050390A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
US7928238B2 (en)	2006-05-11	2011-04-19	Janssen Pharmaceutica Nv	1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors
WO2007134149A2 (en) *	2006-05-11	2007-11-22	Janssen Pharmaceutica N.V.	3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
US20160331729A9 (en)	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
US8426439B2 (en) *	2007-04-11	2013-04-23	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
MX2009013293A (es)	2007-06-04	2010-02-15	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
UA107562C2 (uk)	2008-12-05	2015-01-26		Спосіб лікування псоріазу
LT2396081T (lt)	2009-02-16	2017-09-11	Nogra Pharma Limited	Alkilamido junginiai ir jų panaudojimas
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2798911C (en)	2010-05-19	2018-07-03	Unilever Plc	Theobromine for increasing hdl-cholesterol
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es)	2011-02-25	2017-05-26	Merck Sharp & Dohme	Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2013082106A1 (en)	2011-12-02	2013-06-06	The General Hospital Corporation	Differentiation into brown adipocytes
AU2013217933B2 (en)	2012-02-09	2017-11-30	Nogra Pharma Limited	Methods of treating fibrosis
AU2013248397A1 (en)	2012-04-18	2014-10-02	Nogra Pharma Limited	Methods of treating lactose intolerance
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
KR20160003641A (ko) *	2013-04-30	2016-01-11	쓰리엠 이노베이티브 프로퍼티즈 컴파니	폴리(벤족사진)의 제조 방법
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2016007823A1 (en) *	2014-07-10	2016-01-14	Mallinckrodt Llc	Process for preparing substituted phenylalkanes
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298B1 (en)	2016-12-20	2026-03-11	Merck Sharp & Dohme LLC	Antidiabetic spirochroman compounds
AU2020217884B2 (en)	2019-02-08	2025-02-20	Nogra Pharma Limited	Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CN113968781A (zh) *	2021-11-11	2022-01-25	上海吉奉生物科技有限公司	一种(s)-2-羟基-3-邻甲基丙酸的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0816316A4 (en) *	1995-03-10	1999-06-02	Nitto Chemical Industry Co Ltd	Process for producing 1,2-ethanediol derivatives
JP2002507543A (ja) *	1998-05-27	2002-03-12	ドクター・レディーズ・リサーチ・ファウンデーション	二環系化合物、その製造方法およびそれらを含有する薬学的組成物
JP2002543194A (ja)	1999-04-28	2002-12-17	ドクター・レディーズ・ラボラトリーズ・リミテッド	置換二環系ヘテロ環化合物、その製造方法、並びに抗肥満症及び抗高コレステロール血症剤としてのこれらの使用
SE9904421D0 (sv) *	1999-12-03	1999-12-03	Astra Ab	New compounds
AU2002212672A1 (en)	2000-10-12	2002-04-22	Dr. Reddy's Research Foundation	Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them

2002
- 2002-10-15 IL IL16143102A patent/IL161431A0/xx unknown
- 2002-10-15 BR BR0213380-6A patent/BR0213380A/pt not_active Application Discontinuation
- 2002-10-15 CN CNA028238222A patent/CN1596249A/zh active Pending
- 2002-10-15 PL PL02369655A patent/PL369655A1/xx not_active Application Discontinuation
- 2002-10-15 US US10/492,452 patent/US20110105748A1/en not_active Abandoned
- 2002-10-15 EP EP02801466A patent/EP1436247A1/en not_active Withdrawn
- 2002-10-15 PL PL02369732A patent/PL369732A1/xx not_active Application Discontinuation
- 2002-10-15 JP JP2003536221A patent/JP2005527480A/ja not_active Withdrawn
- 2002-10-15 NZ NZ532285A patent/NZ532285A/en unknown
- 2002-10-15 WO PCT/IB2002/004274 patent/WO2003033456A1/en not_active Ceased
- 2002-10-15 HR HR20040349A patent/HRP20040349A2/hr not_active Application Discontinuation
- 2002-10-15 HU HU0401649A patent/HUP0401649A3/hu unknown
- 2002-10-15 HU HU0401647A patent/HUP0401647A3/hu unknown
- 2002-10-15 EP EP02775090A patent/EP1436268A1/en not_active Withdrawn
- 2002-10-15 BR BR0213350-4A patent/BR0213350A/pt not_active IP Right Cessation
- 2002-10-15 CN CNA028227239A patent/CN1589258A/zh active Pending
- 2002-10-15 JP JP2003536197A patent/JP2005505617A/ja active Pending
- 2002-10-15 IL IL16142902A patent/IL161429A0/xx unknown
- 2002-10-15 HR HR20040350A patent/HRP20040350A2/xx not_active Application Discontinuation
- 2002-10-15 CA CA002463685A patent/CA2463685A1/en not_active Abandoned
- 2002-10-15 WO PCT/IB2002/004275 patent/WO2003033481A1/en not_active Ceased
- 2002-10-15 CA CA002463686A patent/CA2463686A1/en not_active Abandoned
- 2002-10-15 US US10/492,454 patent/US7365064B2/en not_active Expired - Fee Related
2004
- 2004-04-15 ZA ZA200402858A patent/ZA200402858B/xx unknown
- 2004-04-16 ZA ZA200402910A patent/ZA200402910B/en unknown
- 2004-05-14 NO NO20041994A patent/NO20041994L/no not_active Application Discontinuation
- 2004-05-14 NO NO20041998A patent/NO20041998L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20041998D0 (no)	2004-05-14
US7365064B2 (en)	2008-04-29
HUP0401647A3 (en)	2008-05-28
US20050113368A1 (en)	2005-05-26
JP2005527480A (ja)	2005-09-15
NO20041998L (no)	2004-07-02
PL369732A1 (en)	2005-05-02
IL161431A0 (en)	2004-09-27
HUP0401647A2 (hu)	2004-11-29
HUP0401649A2 (hu)	2004-11-29
EP1436268A1 (en)	2004-07-14
NZ532285A (en)	2005-11-25
PL369655A1 (en)	2005-05-02
WO2003033481A1 (en)	2003-04-24
CA2463686A1 (en)	2003-04-24
HUP0401649A3 (en)	2007-05-29
HRP20040350A2 (en)	2005-06-30
HRP20040349A2 (en)	2005-06-30
JP2005505617A (ja)	2005-02-24
CA2463685A1 (en)	2003-04-24
EP1436247A1 (en)	2004-07-14
IL161429A0 (en)	2004-09-27
BR0213350A (pt)	2004-10-13
CN1589258A (zh)	2005-03-02
US20110105748A1 (en)	2011-05-05
CN1596249A (zh)	2005-03-16
ZA200402858B (en)	2005-01-12
WO2003033456A1 (en)	2003-04-24
ZA200402910B (en)	2005-01-13
BR0213380A (pt)	2005-02-01

Legal Events

Date	Code	Title	Description
2008-05-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20024808L (no)	2002-10-04	FremgangsmÕte ved syntesen av perindopril og farmasöytisk akseptable salter derav
NO20030844L (no)	2003-02-25	Fremgangsmåte for fremstilling av N-aryl-antranilinsyrer og derivater derav
NO20015156D0 (no)	2001-10-22	5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
NO20031694L (no)	2003-04-11	Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
NO20032726L (no)	2003-06-16	Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav
NO20024176L (no)	2002-10-29	Farmasöytiske preparater inneholder derivater av 3-amino- azetidin, de nye derivater og deres fremstilling
NO20024623L (no)	2002-11-08	Ny fremgangsmÕte for fremstilling av kondensert imidazopyridinderivat og ny krystallform
ZA200402858B (en)	2005-01-12	Novel beta-phenyl-alpha-oxysubstituted propionic derivatives; process for its preparation and their use in the preparation of pharmaceutically important compounds.
NO20025029L (no)	2002-10-18	Nye epotilonderivater, fremgangsmÕte for fremstilling derav og deres farmasöytiske anvendelse
NO20023400D0 (no)	2002-07-15	Nye forbindelser med lipid- og kolesterolnedsettende virkning, fremgangsmåte ved deres fremstilling og farmasöytiskpreparat
DK1674456T3 (da)	2008-10-27	Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20013569L (no)	2001-07-19	Fremgangsmate ved fremstilling av L-fenylephrine-hydroklorid
NO20023662L (no)	2002-09-27	Nye heterocykliske derivater, fremgangsmåte ved fremstilling og farmasöytiske sammensetninger inneholdende det samme
NO20016389D0 (no)	2001-12-27	Fremgangsmåte for fremstilling av substituerte cyklopentanderivater og nye krystallinske strukturer derav
NO20033433L (no)	2003-09-25	Fremgangsmåte for fremstilling av 2-(2-pyridylmetyl)sulfinyl- 1H-benzimidasol
NO20010522L (no)	2001-08-01	Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO326689B1 (no)	2009-01-26	Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
NO20003555L (no)	2002-01-11	Fremgangsmåte ved fremstilling av konstruksjonselementer og de resulterende elementer
NO20031754D0 (no)	2003-04-15	Fremgangsmåte for fremstilling av mesylater av piperzinderivater
NO20025069D0 (no)	2002-10-22	Ny stabil krystall av tiazolidindionderivat og fremgangsmÕte for fremstilling av det samme
NO20042640L (no)	2004-06-23	Fremgangsmate for fremstilling av ekinocandinderivater
NO20035538D0 (no)	2003-12-11	Fremgangsmåte for fremstilling av zaleplon
NO20030515D0 (no)	2003-02-03	Fremgangsmåte for fremstilling av dinapsolin
NO20035586L (no)	2003-12-15	Fremgangsmate for fremstilling av cykloheksanol-derivater
DK1353912T3 (da)	2006-01-09	2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse